Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab With/Without Involved Lesions Irradiation as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer: a Phase 2, Double Cohort Clinical Trial

NCT06764680 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06764680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab With/Without Involved Lesions Irradiation as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer: a Phase 2, Double Cohort Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
December 31, 2024
Completion date
December 31, 2026
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, colorectal cancer metastatic, immunotherapy, radiotherapy, intensity-modulated, targeted therapy